OBJECTIVES We sought to evaluate the prognostic value of cardiac troponin I (cTnI) in asymptomatic, ambulatory patients with chronic renal failure treated with long-term hemodialysis. BACKGROUND Smaller, short-term follow-up studies on this subject have given conflicting results. METHODS A total of 126 ambulatory patients with chronic renal failure treated with long-term hemodialysis were f...

BACKGROUND Cardiac troponin I (cTnI) is useful for detection of cardiac myocyte damage, but its efficacy in detecting various stages of dilated cardiomyopathy (DCM) in Doberman Pinschers is unclear. OBJECTIVES To evaluate the diagnostic value of cTnI in various stages of DCM in Dobermans. ANIMALS Six hundred and fifty-three cTnI measurements of 336 Doberman Pinschers. METHODS Using a long...

BACKGROUND We aimed to investigate the effects of sex, prevalent cardiovascular disease (CVD), and aging on the 99th percentile of cardiac troponin I (cTnI). METHODS cTnI was measured using a high-sensitivity assay (Abbott Diagnostics) in 814 community-dwelling individuals at both 70 and 75 years of age. We determined the cTnI 99th percentiles separately using nonparametric methods in the tot...

OBJECTIVES This study sought to assess changes in troponin levels, underlying conditions, and the prognostic implications in elderly subjects from the community. BACKGROUND Cardiac troponin levels are often detectable in community dwellers when sensitive assays are applied. However, information on the course of troponin levels over time is limited. METHODS Cardiac troponin I (cTnI) was meas...

OBJECTIVES Successful prediction of cardiac complications early in the course of acute ischaemic stroke could have an impact on the clinical management. Markers of myocardial injury on admission deserve investigation as potential predictors of poor outcome from stroke. METHODS We prospectively investigated 330 consecutive patients with acute ischaemic stroke admitted to our emergency departme...

BACKGROUND Significant analytic variability exists between the multiple assays for cardiac troponin I (cTnI) approved for clinical use. Until adequate cTnI standardization is possible, an evidence-based approach evaluating each assay at specific thresholds appears warranted. METHODS We examined the efficacy of three cTnI assays for predicting death, myocardial infarction (MI), or the composit...

OBJECTIVE To determine the correlation of cardiac troponin I (cTnI) 10 folds upper limit of normal (ULN) and extent of coronary artery disease (CAD) in Non-ST-elevation myocardial infarction (NSTEMI). METHODS A cross-sectional study was conducted on 230 consecutive NSTEMI patients admitted in Tabba Heart Institute, Karachi between April to December 2008. cTnI was measured using MEIA method. A...

I have chosen to address the argument of why cardiac troponin I (cTnI) assays will likely never be standardized. It is not that I do not wish it would happen, but I think the scientific, evidence-based story I will present regarding this cardiac specific protein will speak for itself. As a means to present this argument, I would like to consider the following analogy. I am an avid trail runner....

Cardiac troponin I (cTnI) is a regulatory protein unique to myocardium. We used a cardiospecific 30-min ELISA to measure cTnI in EDTA-plasma samples serially drawn from 28 patients before and after coronary artery bypass grafting (CABG)--26 elective and 2 salvage cases. The cTnI increase in 22 of the elective CABG patients, who did not have perioperative myocardial infarction (not-PMI), reflect...